Pfizer is set to gain a NICE recommendation for its renal cell carcinoma treatment Inlyta, two years after its launch. The drug is to be used as second line therapy after failure of prior ...

The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...

The FRUSICA-2 study is a randomised, open-label, active-controlled study to evaluate the efficacy and safety of Tyvyt and ...